Individualized Care for Patients with Cancer — A Work in Progress
- 30 December 2004
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 351 (27) , 2865-2867
- https://doi.org/10.1056/nejme048300
Abstract
During the past two decades, molecular biologists have been dissecting the heterogeneity of human cancer — a diversity that oncologists have long appreciated, especially because patients who have similar stages and grades of cancer and whose tumors have similar histologic features have a broad range of clinical outcomes. Some cancers respond to treatment; others do not. Some patients have a recurrence of cancer; others are cured.Molecular markers promise the ability to estimate prognoses and predict responses to particular treatments with greater precision than is possible with clinical findings. With further refinement of molecular diagnostics, the care of patients with . . .Keywords
This publication has 12 references indexed in Scilit:
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerNew England Journal of Medicine, 2004
- E2F1 Expression is Related with the Poor Survival of Lymph Node-positive Breast Cancer Patients Treated with Fluorouracil, Doxorubicin and CyclophosphamideBreast Cancer Research and Treatment, 2003
- Meeting Highlights: Updated International Expert Consensus on the Primary Therapy of Early Breast CancerJournal of Clinical Oncology, 2003
- Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancerThe Lancet, 2003
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerNew England Journal of Medicine, 2002
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialThe Lancet, 2002
- Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysisThe Lancet, 2001
- Superior Efficacy of Letrozole Versus Tamoxifen as First-Line Therapy for Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Study of the International Letrozole Breast Cancer GroupJournal of Clinical Oncology, 2001
- Polychemotherapy for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Tamoxifen for early breast cancer: an overview of the randomised trialsThe Lancet, 1998